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Background
Cytophagic histiocytic panniculitis (CHP) is a rare lobu-
lar panniculitis, characterized by subcutaneous prolifera-
tion of benign-appearing cytophagic histiocytes and
lymphocytes often associated with systemic macrophage
activation syndrome (MAS). Its pathogenesis is
unknown.
Aim
To report on immunohistochemical findings on skin
CHP tissue.
Patients
A 10-month-old year boy and a 4-month-old-year girl pre-
sented with multiple erythematous and indurated noduless
on the limbs, and developed high-grade fever and bio-
logical features suggestive of MAS several months after
the onset of cutaneous disease. Serologic test for EBV was
negative and bone marrow examination revealed hemo-
phagocytosis. A homozygous splicing mutation for the
UNC13D gene encoding for Munc 13-4 was present in
patient 1, but NK cell cytotoxicity and degranulation
assays, and expression of Munc 13-4 protein were normal.
No mutation was found in Patient 2. Prednisone alone
failed to induce a sustained remission which was obtained
by adding cyclosporine A.
Results
Skin biopsy specimen revealed a lobular panniculitis with
areas of necrosis in both patients. The inflammatory infil-
trate consisted of lymphocytes and macrophages in der-
mis and hypodermis, and signs of hemophagocytosis.
There were no atypical cells. These findings were consis-
tent with CHP. Immunohistochemical stainings showed
numerous CD68 macrophages and CD8+lymphocytes,
expressing HLA-DR, and a few CD4+ cells. Lymphocytes
expressed IFN-g and macrophages TNF-a and IL6. These
immunohistochemical features were characteristic of
MAS.
Conclusion
This study provides evidence that CHP may represent
MAS in situ in adipose tissue; and emphasized that
CHP can precede systemic signs of MAS by several
months.
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